AstraZeneca PLC Valuation
| AZNCF Stock | USD 136.20 2.04 1.48% |
At this time, the firm appears to be overvalued. AstraZeneca PLC shows a prevailing Real Value of $111.58 per share. The current price of the firm is $136.2. Our model approximates the value of AstraZeneca PLC from analyzing the firm fundamentals such as Return On Equity of 0.0863, current valuation of 241.1 B, and Profit Margin of 0.07 % as well as examining its technical indicators and probability of bankruptcy. In general, most investors favor locking in undervalued instruments and disposing overvalued instruments since, at some point, asset prices and their ongoing real values will blend.
Overvalued
Today
Please note that AstraZeneca PLC's price fluctuation is very steady at this time. Calculation of the real value of AstraZeneca PLC is based on 3 months time horizon. Increasing AstraZeneca PLC's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Our valuation method for AstraZeneca PLC is useful when determining the fair value of the AstraZeneca pink sheet, which is usually determined by what a typical buyer is willing to pay for full or partial control of AstraZeneca PLC. Since AstraZeneca PLC is currently traded on the exchange, buyers and sellers on that exchange determine the market value of AstraZeneca Pink Sheet. However, AstraZeneca PLC's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 136.2 | Real 111.58 | Hype 136.2 |
The real value of AstraZeneca Pink Sheet, also known as its intrinsic value, is the underlying worth of AstraZeneca PLC Company, which is reflected in its stock price. It is based on AstraZeneca PLC's financial performance, assets, liabilities, growth prospects, management team, or industry conditions. The intrinsic value of AstraZeneca PLC's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence AstraZeneca PLC's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of AstraZeneca PLC helps investors to forecast how AstraZeneca pink sheet's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of AstraZeneca PLC more accurately as focusing exclusively on AstraZeneca PLC's fundamentals will not take into account other important factors: AstraZeneca PLC Valuation Ratios as Compared to Competition
Comparative valuation techniques use various fundamental indicators to help in determining AstraZeneca PLC's current stock value. Our valuation model uses many indicators to compare AstraZeneca PLC value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across AstraZeneca PLC competition to find correlations between indicators driving AstraZeneca PLC's intrinsic value. More Info.AstraZeneca PLC is number one stock in price to earning category among related companies. It is number one stock in price to book category among related companies fabricating about 0.14 of Price To Book per Price To Earning. The ratio of Price To Earning to Price To Book for AstraZeneca PLC is roughly 7.17 . Comparative valuation analysis is a catch-all model that can be used if you cannot value AstraZeneca PLC by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for AstraZeneca PLC's Pink Sheet. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the AstraZeneca PLC's earnings, one of the primary drivers of an investment's value.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates AstraZeneca PLC's worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in AstraZeneca PLC and how it compares across the competition.
About AstraZeneca PLC Valuation
The pink sheet valuation mechanism determines the current worth of AstraZeneca PLC on a weekly basis. We use both absolute as well as relative valuation methodologies to arrive at the intrinsic value of AstraZeneca PLC. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of AstraZeneca PLC based exclusively on its fundamental and basic technical indicators. By analyzing AstraZeneca PLC's financials, quarterly and monthly indicators, and its related drivers such as dividends, operating cash flow, and various types of growth rates, we attempt to find the most accurate representation of AstraZeneca PLC's intrinsic value. In some cases, mostly for established, large-cap companies, we also incorporate more traditional valuation methods such as dividend discount, discounted cash flow, or asset-based models. As compared to an absolute model, our relative valuation model uses a comparative analysis of AstraZeneca PLC. We calculate exposure to AstraZeneca PLC's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to AstraZeneca PLC's related companies.AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom. Astrazeneca Plc operates under Drug ManufacturersGeneral classification in the United States and is traded on OTC Exchange. It employs 83100 people.
8 Steps to conduct AstraZeneca PLC's Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates AstraZeneca PLC's potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct AstraZeneca PLC's valuation analysis, follow these 8 steps:- Gather financial information: Obtain AstraZeneca PLC's financial statements, including balance sheets, income statements, and cash flow statements.
- Determine AstraZeneca PLC's revenue streams: Identify AstraZeneca PLC's primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research AstraZeneca PLC's industry and market trends, including the size of the market, growth rate, and competition.
- Establish AstraZeneca PLC's growth potential: Evaluate AstraZeneca PLC's management, business model, and growth potential.
- Determine AstraZeneca PLC's financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate AstraZeneca PLC's estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
A single share of AstraZeneca PLC represents a small ownership stake in the entity. As a stockholder of AstraZeneca, your percentage of company ownership is determined by dividing the number of shares you own by the total number of shares outstanding and then multiplying that amount by 100. Owning stock in a company generally confers both corporate voting rights and income from any dividends paid to the stock owner.
AstraZeneca PLC Dividends Analysis For Valuation
Please note that AstraZeneca PLC has scaled down on payment of dividends at this time.
There are various types of dividends AstraZeneca PLC can pay to its shareholders, and the actual value of the dividend is determined on a per-share basis. It is to be paid equally to all of AstraZeneca shareholders on a specific date, known as the payable date. The cash dividend is the most common type of dividend payment - it is the payment of actual cash from AstraZeneca PLC directly to its shareholders. There are other types of dividends that companies can issue, such as stock dividends or asset dividends. When AstraZeneca pays a dividend, it has no impact on its enterprise value. It does, however, lowers the Equity Value of AstraZeneca PLC by the value of the dividends paid out.
AstraZeneca PLC Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines. Note, investing in growth stocks can be very risky. If the company such as AstraZeneca PLC does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 1.5 B | |
| Quarterly Earnings Growth Y O Y | -0.451 | |
| Forward Price Earnings | 18.2815 | |
| Retained Earnings | -574 M |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in AstraZeneca PLC. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators. Note that the AstraZeneca PLC information on this page should be used as a complementary analysis to other AstraZeneca PLC's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.
Complementary Tools for AstraZeneca Pink Sheet analysis
When running AstraZeneca PLC's price analysis, check to measure AstraZeneca PLC's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AstraZeneca PLC is operating at the current time. Most of AstraZeneca PLC's value examination focuses on studying past and present price action to predict the probability of AstraZeneca PLC's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AstraZeneca PLC's price. Additionally, you may evaluate how the addition of AstraZeneca PLC to your portfolios can decrease your overall portfolio volatility.
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Stocks Directory Find actively traded stocks across global markets | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges |